Ropack, a provider of contract manufacturing and packaging services for the pharmaceutical and nutraceutical industries, said today it has established a U.S. presence by purchasing two pharmaceutical facilities in Long Island, New York.
The two buildings total 213,700 square feet and were formerly operated by Forest Laboratories—acquired last year for about $28 billion by Actavis, now known as Allergan. The price of the acquisition was not disclosed.
The company said its acquisition will significantly expand its capabilities by adding research and development, formulation, lab analysis, and commercial and clinical manufacturing—complementing its established solid oral dosage packaging and clinical study distribution operations.
Ropack said the acquisition was part of its strategic expansion plan.
“It has been a longstanding goal to broaden our service offerings,” Ropack president and CEO, Yves Massicotte, said in a statement. “To establish a presence in the United States at the same time makes this acquisition ideal.”
Ropack said its activities in the U.S. will be managed through Ropack USA, which will be known with Ropack as “Ropack Pharma Solutions.”
“The purchase of these two state-of-the-art pharmaceutical facilities on Long Island will enable Ropack Pharma Solutions to provide its current and future customers with comprehensive solid oral dosage development, manufacturing and packaging solutions,” added Paul Dupont, vp of marketing and business development for Ropack. “This acquisition will add considerable capacity and key technologies to support projects from formulation development through commercialization.”
Celebrating its 40th anniversary next year, Ropack operates four facilities in Montreal for the packaging of solid oral dosage in bottles, flip-top vials, blister packs, stick-packs and sachets. The company is also a Canadian clinical trial depot.
